BYSI Stock — BeyondSpring Inc

BeyondSpring Inc (BYSI)

Updated October 16, 2026.

BYSI is a Stock. Total return is -96.7% over the past 9.6 years, 371.8 points behind SPY at 275.1%.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing therapies focused on oncology and immunology, with its lead asset being Plinabulin, a selective immunomodulating agent that has completed Phase III trials for non-small cell lung cancer and chemotherapy-induced neutropenia prevention. The company does not currently distribute to shareholders. BeyondSpring appeals to investors seeking exposure to early-stage oncology drug development rather than current income.

BYSI performance versus SPY

Price and return data through 2026-10-16.

Total return is -96.7% over the past 9.6 years, 371.8 points behind SPY at 275.1%. Over the past year its total return — price change plus distributions reinvested — is -68.7%. Its deepest 1-year drawdown was 76.2%.

BYSI key facts

Asset type

Stock

Asset class

Equity

Inception date

03/09/2017

Distribution frequency

None

Last close

$0.56 (as of 2026-10-16)

Market cap

$22,994,203

Average volume

11166.0

Beta

-0.207

Payout ratio

0.0%

Forward P/E

10.5374

EPS

$-0.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BYSI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 76.2%.

Who may consider BYSI — and who may not

It is a weaker fit for investors who need monthly cash flow (BYSI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BYSI

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions